Abstract

Brugada Syndrome (BrS) presents a particularly challenging clinical field for cardiologists due to its associated potentially lethal and often unpredictable arrhythmic risk [1]. While secondary prevention in patients with documented ventricular arrhythmias is relatively straightforward, leading to the inevitable implantation of an implantable cardioverter-defibrillator (ICD), primary prevention is more debated. The challenge lies in effectively protecting the patient from sudden cardiac death (SCD) while avoiding overtreatment and potential complications from defibrillator implantation [2].

References

1. Brugada J., et al. “Present Status of Brugada Syndrome: JACC State-of-the-Art Review”. J Am Coll Cardiol 72 (2018): 1046-1059.
2. Jespersen CHB., et al. “Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety: a Danish nationwide study”. Europace 25.5 (2023).
3. Mascia G., et al. “Brugada syndrome and syncope: a practical approach for diagnosis and treatment”. Europace 23 (2021): 996-1002.
4. Bergonti M., et al. “Implantable loop recorders in patients with Brugada syndrome: the BruLoop study”. Eur Heart J 45 (2024): 1255-1265.

Citation

Giuseppe Franculli., et al. “A new horizon for Brugada Syndrome: the challenge launched by the BruLoop Study". Clareus Scientific Medical Sciences 2.1 (2025): 01-03.

Copyright

© 2025 Giuseppe Franculli., et al. Licensee Clareus Scientific Publications. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.